Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) Following SARS-CoV2 Vaccination

Area of Science:

• Immunology
• Rheumatology
• Vaccinology

Background:

• The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine is widely administered.
• Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) is a recognized phenomenon following various exposures.
• Polymyalgia rheumatica (PMR) is an inflammatory condition primarily affecting older adults.

Observation:

• A 67-year-old male presented with joint swelling, muscle weakness, pain, and anemia post-second dose of the BNT162b2 mRNA COVID-19 vaccine.
• Clinical presentation met diagnostic criteria for both PMR and ASIA.
• Differential diagnoses were systematically excluded through comprehensive workup.

Findings:

• The patient's symptoms were consistent with a diagnosis of vaccine-associated PMR and ASIA.
• The co-occurrence of PMR and ASIA was noted, suggesting a potential link.
• Treatment with corticosteroid therapy resulted in significant clinical improvement.

Implications:

• This case highlights the potential for mRNA COVID-19 vaccines to trigger autoimmune syndromes like PMR and ASIA.
• Vaccine-associated autoimmune syndromes can present with diverse clinical manifestations.
• A high index of suspicion is crucial for early diagnosis and management of these rare vaccine complications.